From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples

Gaetano Facchini 1 *, Chiara Della Pepa 1, Carla Cavaliere 4, Sabrina C. Cecere 4, Marilena Di Napoli 1, Carmine D’Aniello 2, Anna Crispo 4, Gelsomina Iovane 1, Piera Maiolino 4, Teresa Tramontano 4, Raffaele Piscitelli 4, Salvatore Pisconti 2, Maurizio Montella 3, Massimiliano Berretta 6, Domenico Sorrentino 6, Sisto Perdonà 6 and Sandro Pignata 1

1 Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy, 2 Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy; 3 Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Fondazione Istituto Nazionale Tumori, Naples, Italy, 4 Pharmacy Unit, Istituto Nazionale Tumori, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy, 5 Division of Medical Oncology–CRO, Aviano, Italy, 6 Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

Background: The efficacy of Vinflunine, after failure of platinum-based chemotherapy in patients with metastatic or recurrent Transitional Cell Cancer of the Urothelial Tract, TCCU, has been demonstrated in an international, randomized, phase III trial comparing Vinflunine plus Best Supportive Care, BSC, with BSC alone. On the basis of that study vinflunine has been approved by the European Medicine Association, EMA, for treatment of TCCU patients after failure of a platinum treatment. However, since data in clinical trials often differ from routine clinical practice due to unselected population and less strict monitoring, “real life” experiences are very helpful to verify the efficacy of a new therapy.

Methods: This was a spontaneous, observational, retrospective study involving 43 patients with metastatic TCCU treated with vinflunine at our cancer center, data about demographics, disease characteristics, and previous treatments were collected and outcome and toxicities of vinflunine were analyzed.

Results: 41 of 43 patients were eligible for RR analysis, the Overall RR was 12%, the Disease Control Rate was 29%; when including only patients treated in II line the DCR rose to 33%; the median PFS and the median OS were 2.2 and 6.9 months, respectively.

Conclusion: Our findings were consistent with the outcome data emerged in the phase III randomized trial and in the other observational studies conducted all around Europe in the last 2–3 years. This experience supports the use of vinflunine in patients with advanced TCCU as effective and manageable antineoplastic drug.

Keywords: vinflunine, transitional cell cancer of the urothelial tract, response rate, progression free survival, overall survival
INTRODUCTION

Transitional cell cancer of the urothelial tract, TCCU, is the sixth most common type of cancer in western countries (Siegel et al., 2013; Franco et al., 2014), in most cases it involves the bladder but may also origin from the ureter or the renal pelvis; the estimated number of deaths from bladder cancer in US in 2015 are 16,000 which means that the need of new therapeutic approaches is extremely urgent (Bladder cancer incidence and mortality National Cancer Institute1; Leopardo et al., 2013).

Advanced TCCU is considered a relatively chemosensitive tumor due to the high Response Rate, RR, observed in first line with platinum-based regimens, varying from 40 to 70% (Von der Maase et al., 2005; Roberts et al., 2006; Bellmunt et al., 2012; Ferro et al., 2012; Marra et al., 2013; Cavaliere et al., 2014), nevertheless the duration of response is limited and when progression after primary treatment occurs the outcome is generally poor (Iaffaioli et al., 1997; Strocchi et al., 2004). Several regimens have been tested in the recurrent setting, including both single agents (Albers et al., 2002; Vaughn et al., 2002; Franco et al., 2011) and combinations (Bellmunt et al., 2002; Iaffaioli et al., 2006; Lin et al., 2007; Marra et al., 2008) but they showed modest activity often associated with significant toxicity. Interesting results in patients progressed after platinum were reported with the gemcitabine-paclitaxel doublet which demonstrated relevant activity in two phase II trials (Sternberg et al., 2001; Reimann et al., 2001) however, up to very recently, a standard second line treatment did not exist. Vinflunine is an antineoplastic agent belonging to the vinca alkaloids family, such drugs act inducing apoptosis by prevention of microtubule assembly during mitosis (Aparicio et al., 2012). The most important advantage of this novel molecule, when compared with the other agents of the same class, is the higher inhibition of microtubules dynamics thus strongly acting on mitotic spindle rather than on the axonal tubuline, vinflunine exposes patients to a minor risk of neurotoxicity (Kruczenski and Hill, 2001; Braguer et al., 2008).

The efficacy of Vinflunine after failure of platinum-based chemotherapy has been proved in two phase II trials involving a cohort of 51 and 175 patients respectively (Culine et al., 2006; Vaughn et al., 2009). In the work by Culine et al. (2006) the reported Overall Response Rate, ORR, was 18% (95% Confidence Interval, CI: 8.4–30.9%) and the Disease Control Rate (Partial Response, PR, plus Stable Disease, SD), DCR, was 67% (95%CI: 52.1–79.3%); the median duration of response was 9.1 months (95% CI: 4.2–15.0); the median Progression Free Survival, PFS, was 3.0 months (95% CI: 2.4–3.8); the median Overall Survival, OS, was 6.6 months (95% CI: 4.8–7.6; Culine et al., 2006). In the second phase II study, by Vaughn et al, the observed RR with Vinflunine was 15% (95% CI, 9–21%), the median duration of response was 6.0 months; the authors reported a median PFS of 2.8 months and a median OS of 8.2 months (Vaughn et al., 2009). In both the phase II clinical trials the side effects were manageable and myelosuppression was the main issue followed by constipation and fatigue (Culine et al., 2006; Vaughn et al., 2009).

The encouraging results reported in such studies led to an international, randomized, phase III trial comparing Vinflunine plus Best Supportive Care, BSC, with BSC alone (Bellmunt et al., 2009). Bellmunt et al. showed that Vinflunine significantly improved PFS (3 vs. 1.5 months, $P = 0.0012$); ORR (16 vs. 0%, $P = 0063$) and DCR (41.1 vs. 24.8%, $P = 0.0063$). The primary endpoint of the study was a 2 months advantage in the OS, this was achieved (6.9 vs. 4.6) but was not statistically significant ($p = 0.29$) in the Intention To Treat, ITT, population $(n = 365)$ while it was confirmed (6.9 vs. 4.3) and reached the statistical significance $(p = 0.04)$ in the eligible population $(n = 357)$.

These data were then confirmed at a long-term follow up at more than 3, 5 years (Bellmunt et al., 2013). Vinflunine was the first drug in September 2009, receiving the approval from the European Medicine Association, EMA, for treatment of TCCU patients after failure of a platinum-based regimen (European Medicine Agency2).

Usually the experience in clinical practice significantly differs from the trials findings mainly because of the minor patients selection and the lack of a so strict patients monitoring, observational studies run in routine clinics may help to provide a more realistic scenario though they have several limits related to the number of subjects, the often retrospective design and the potential statistical bias.

We retrospectively reviewed our experience with Vinflunine in the treatment of advanced TCCU.

PATIENTS AND METHODS

This was a spontaneous retrospective study, approved by the local ethic committee, looking at patients with metastatic TCCU treated with Vinflunine at the National Cancer Institute, Giovanni Pascale Foundation, in Naples, Italy. Inclusion criteria included: age > 18 years old, histologically-proven diagnosis of TCCU, stage IV disease, measurable lesions at the CT scan, prior or current treatment with Vinflunine (any line), signed informed consent (if patient had not deceased). Retrieving from our archives the data about metastatic TCCU patients, we found 43 patients who have received Vinflunine from February 2012 to March 2015 in either second or subsequent lines.

As baseline characteristics we evaluated demographics and previous treatment data, we also analyzed several risk factors of interest such as ECOG (Eastern Cooperative Oncology Group) Performance Status, PS, renal function, anemia and visceral involvement and their effect on survival. In terms of outcome we described Response Rate, RR (either overall and II vs. subsequent lines), the Progression Free Survival, PFS, and the OS, Overall Survival.

We closed the data collection on 10th March 2015, estimation of likelihood events for PFS and OS were calculated according to the Kaplan-Meier method, statistical differences between curves were calculated using log-rank test. The Cox proportional hazards model was used to test the effect of the considered risk factors on survival in multivariate analyses; Hazard Ratios (HRs) and 95% Confidence Interval (CIs) were estimated, adjusting for variables that were significant at univariate analysis; a $p < 0.05$

---

1http://www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional/page1.

2http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000983/human_med_000866.jsp&mid=WCB01ac058001d124.
was considered significant. Statistical analysis was performed using SPSS (version 21; SPSS, Inc., Chicago, IL).

RESULTS

Baseline Characteristics

As previously mentioned we enrolled 43 subjects, 40 patients were male (93%), median age was 63.5 (range 41–76), 34 patients (79%) had bladder urothelial carcinoma while 9 (21%) had other TCCU. As to treatment 25 patients (58%) have had surgery; 11 patients (26%) have received a perioperative treatment which mainly consisted of adjuvant chemotherapy. As to previous regimens, all patients undergone a first line chemotherapy prior to Vinflunine, 56% with carboplatin, 37% with cisplatin, 7% with gemcitabine and paclitaxel. Though a small number of patients, 8 (19%) received Vinflunine as III or IV line the most of our cohort were given Vinflunine as II line; patients experienced relapse/progression less than 6 months after completion of the prior chemotherapy in 74% of cases.

We focused on several prognostic factors to verify their impact on survival: (i) anemia; (ii) poor PS; (iii) visceral involvement, and (iv) compromised renal function were individuated as potentially relevant risk factors. Anemia, defined as hemoglobin < 10 mg/dL, poor PS, and liver metastases were demonstrated to be significant prognostic factors by Sonpavde et al., however, compared to their model, we considered “poor” PS ≥ 2 rather than > 0 and “presence of liver metastases” was replaced by “visceral involvement” (Sonpavde et al., 2013). Though reduced renal function failed to predict survival in TCCU patients in previous papers (Bellmunt et al., 2010; Galsky et al., 2012) we decided to include such parameter, defined as Creatinine Clearance < 40 ml/min in our analysis in order to confirm or deny this lack of association.

We found that, when starting Vinflunine, 10% of our patients had a PS ≥ 2; 40% had a Creatinine Clearance < 60 ml/min (5% < 40 ml/min); 60% had lung or liver metastases; 12% had grade 2 anemia (Hemoglobin, Hb, < 10 mg/dl). Globally at least one risk factor was observed in more than half of the cases while about the 20% presented 2 or more of them.

The baseline characteristics of our cohort are summarized in Tables 1A,B, the former showing demographics and previous treatment data, the latter explaining population features in terms of prognostic risk factors.

Outcome

Forty-one of Forty-three patients were eligible for RR analysis (two patients excluded due to unavailability of post-treatment

| TABLE 1A | Baseline characteristics: demographics and previous treatment.
|---|---|
| n = 43 (%) |
| **AGE** |
| Median | 63.5 |
| Range | 41–76 |
| **SEX** |
| Male | 40 (93) |
| Female | 3 (7) |
| **ORIGIN** |
| Bladder | 34 (79) |
| Other | 9 (21) |
| **SURGERY** |
| Not received | 18 (42) |
| Cistectomy | 22 (51) |
| Nephroureterectomy | 3 (7) |
| **PERIOPERATIVE TREATMENT** |
| Not received | 32 (74) |
| Neoadjuvant | 0 (0) |
| Adjuvant | 11 (26) |
| CT only | 7 (16) |
| RT only | 2 (5) |
| CT + RT | 2 (5) |
| **FIRST-LINE REGIMEN** |
| CBDCA | 24 (56) |
| CDDP | 16 (37) |
| GEM/PTX | 3 (7) |
| **VINFLUNINE LINE** |
| II line | 35 (81) |
| III line | 6 (14) |
| IV line | 2 (5) |
| **TIME TO RELAPSE/PROGRESSION AFTER THE PRIOR CHEMOTHERAPY** |
| ≤6 months | 32 (74) |
| >6 months | 11 (26) |

CT, Chemotherapy; RT, Radiotherapy; CBDCA, Carboplatin; CDDP, Cisplatin; GEM/PTX, Gemcitabine/Paclitaxel.

| TABLE 1B | Baseline characteristics: Risk factors.
|---|---|
| n = 43 (%) |
| **PS** |
| 0 | 3 (7) |
| 1 | 30 (70) |
| ≥2 | 10 (23) |
| **CREATININE CLEARANCE (mL/min)** |
| >60 | 26 (60) |
| 40–60 | 15 (35) |
| <40 | 2 (5) |
| **VISCERAL INVOLVEMENT** |
| No | 17 (40) |
| Yes | 26 (60) |
| **Hgb level mg/dL** |
| ≥10 | 38 (88) |
| <10 | 5 (12) |
| **RISK FACTORS STRATIFICATION** |
| 0 | 9 (21) |
| 1 | 25 (58) |
| ≥2 | 9 (21) |

CT, Chemotherapy; RT, Radiotherapy; CBDCA, Carboplatin; CDDP, Cisplatin; GEM/PTX, Gemcitabine/Paclitaxel.
Facchini et al. Vinflunine in the Treatment of Urothelial Cell Carcinoma

TABLE 2 | Outcome.

| RR (Overall) | n = 41 (%) |
|--------------|------------|
| PR           | 5 (12)     |
| SD           | 7 (17)     |
| DCR          | 12 (29)    |

| RR (II line) | n = 33 (%) |
|--------------|------------|
| PR           | 4 (12)     |
| SD           | 7 (21)     |
| DCR          | 11 (33)    |

| RR (III and IV line) | n = 8 (%) |
|-----------------------|-----------|
| PR                    | 1 (13)    |
| SD                    | 0 (0)     |
| DCR                   | 1 (13)    |

| PFS (months) | |
|--------------|------------|
| mPFS         | n = 38     |
|              | 2.2        |
| mPFS (DCR pts)| n = 12   |
|              | 7.2        |

| OS (months) | |
|-------------|------------|
| mOS (Overall)| n = 43   |
|              | 6.9        |
| mOS (VIN II line) | n = 35 |
|              | 11.8       |
| mOS (VIN III-IV line) | n = 8 |
|              | 5.6        |

RR, Response Rate; PR, Partial Response; SD, Stable Disease; DCR, Disease Control (PR + SD); PFS, Progression Free Survival; mPFS, median PFS; OS, Overall Survival; mOS, median OS; VIN, Vinflunine.

On 10th March 2015, 38 of our 43 patients had progressed (median follow up 24 months) hence were evaluable for PFS, the median PFS resulted 2.2 months in the entire cohort and 7.2 months in the 12 patients who have had PR or SD as best response to Vinflunine (DCR group).

Looking at the survival outcome we found a median OS of 6.9 months; when restricting the evaluation to the 35 patients receiving Vinflunine in II line the value reached the median of 11.8 months.

All the outcome findings are shown in Table 2.

TABLE 3 | Risk of death based on risk factors analysis.

| Risk factor            | HR   | 95% C.I.   | p    |
|------------------------|------|------------|------|
| Hb < 10 g/dL           | 3.4  | 1.26–9.1   | 0.01 |
| Creatinine Cl < 40 ml/min| 3.0  | 1.0–9.3    | 0.05 |
| PS ≥ 2                 | 2.6  | 0.6–12.3   | 0.2  |
| Visceral involvement   | 1.9  | 0.77–4.9   | 0.1  |
| ≥2 risk factors        | 2.6  | 1.1–5.9    | 0.002|

HR, Hazard Ratio; C.I., Confidence Interval; Hb, Haemoglobin; Creatinine Cl, Creatinine Clearance; PS, Performance Status.

As documented in previous works (Bellmunt et al., 2010; Sonpavde et al., 2013), we found that anemia had an effect on survival with an HR of 3.4 (p = 0.01), on the other side, in contrast with data in literature (Bellmunt et al., 2010; Galsky et al., 2012), we observed that altered renal function had an effect on survival (HR 3, p = 0.05) while PS did not (HR 2.6 p = n.s.), however, due to the limited patients cohort, these findings need to be carefully interpreted (Table 3); also the treatment with Vinflunine in II rather than in III or IV line showed to have an effect on survival (Figure 1).

Safety
In our experience Vinflunine appeared as a very manageable therapy, there were no major safety issues and no treatment discontinuations due to toxicity (Table 4). The most frequent non hematological side effects were fatigue (51%), constipation (26%), and abdominal pain (12%) which were grade 3/4 only in

FIGURE 1 | Kaplan-Meier estimates of OS according to VINFLUNINE lines.

TABLE 4 | Safety.

| Adverse event            | Any grade n (%) | Grade 3/4 n (%) |
|--------------------------|-----------------|-----------------|
| Fatigue/asthenia         | 22 (51)         | 1 (2)           |
| Nausea                   | 15 (35)         | 0 (0)           |
| Vomiting                 | 8 (19)          | 0 (0)           |
| Stomatitis/mucositis     | 4 (9)           | 0 (0)           |
| Abdominal pain           | 5 (12)          | 0 (0)           |
| Costipation              | 11 (26)         | 1 (2)           |
| Myalgia                  | 3 (7)           | 0 (0)           |
| Neuropathy sensory       | 3 (7)           | 0 (0)           |
| Alopecia                 | 5 (12)          | 0 (0)           |
| Infusion/injection site reaction | 2 (5) | 0 (0) |
| Anemia                   | 18 (42)         | 2 (5)           |
| Neutropenia              | 31 (72)         | 8 (19)          |
| Febrile neutropenia      | 2 (5)           | 2 (5)           |
| Thrombocytopenia         | 11 (26)         | 2 (5)           |

The bold values highlight the most frequent side effects.
two patients. In regards to mielotoxicity we observed grade 3–4 neutropenia in the 19% of patients and two cases, 5%, of febrile neutropenia (both spontaneously recovered). Infusion/injection site reactions occur in 2 of 43 patients (5%), however roughly 90% of the patients included in this analysis had a venous catheter either PICC-line or PORT-A-CATH.

### DISCUSSION

The introduction of a new treatment into the routine clinical practice usually reveals new aspects in regards to both outcome and safety, with innovative and expensive therapies constantly emerging, the issue of the cost-effectiveness ratio become every day more important and the Healthcare institutions are understandably more and more cautious about budget resources. The observational, non-interventional studies, are crucial to clarify the real impact of a new treatment on the affected population and to provide useful information about cost, side effects, and tolerability in unselected cohorts.

With more than half of our patients presenting with 1 unfavorable risk factor and 20% having 2 or more of them we can say that this was a very “unselected” population however our efficacy findings appear comparable with the outcome observed in the phase III randomized trial (Bellmunt et al., 2009), also the other “real life” experiences (Hegele et al., 2013; Medioni et al., 2013; Castellano et al., 2014; Palacka et al., 2014; Hussain et al., 2015; Moriceau et al., 2015; Retz et al., 2015), which have been conducted all around Europe, in the last 2–3 years, showed equivalent data (see Table 5).

This study confirmed that Vinflunine is a very manageable antineoplastic drug, effective in a setting in which there are very few therapeutic options and patients clinical conditions are often deteriorated due to bulky abdominal disease and poor renal function.

The available retrospective analyses together with our work demonstrate that clinicians can feel confident in administering Vinflunine to unselected patients; fatigue, constipation, and abdominal pain are the most frequent non-hematologic side effects. As to mielotoxicity grade 3–4 neutropenia was reported in 50% of patients in the phase III trial and only in 19% of our cohort, however, due to the retrospective nature of this analysis adverse events may have been somehow underestimated.

The strengths of this study include the number of patients, which is more than acceptable considering that this was a single center experience and Vinflunine became available in Italy only very recently, and the data completeness which consented to make a reliable efficacy statistical analysis. On the other hand our feeling is that the hematology and biochemistry side effects may have been underestimated due to the retrospective nature and that including patients treated in III or subsequent line may have altered the cohort homogeneity.

### CONCLUSION

To the best of our knowledge this is the first work focused on Italian patients treated with Vinflunine, all the European literature support the use of this drug after failure of a previous platinum treatment in patients with advanced TTCU and our study reported outcome data consistent with the findings of the other “real life” trials and not very distant from the randomized phase III trial which included a much more selected population.

### AUTHOR CONTRIBUTIONS

GF, CP, CC, SC, MD, CD, SPI design the study and wrote the manuscript; AC, MM performed the statistical analysis; GI, LP, MB, DS, SPE, SPig performed the data collection; PM, TT, and RP performed the pharmacoeconomical analysis.

---

**TABLE 5 | Vinflunine for metastatic/recurrent TTCU: the phase III trial compared to real-life.**

| References | Country | n | Vinflunine line | RR | DCR | mPFS | mOS |
|------------|---------|---|----------------|----|-----|------|-----|
| Medioni et al., ECCO, 2013 | France | 134 | II | 22 | 51 | 4.2 | 8.2 |
| Castellano et al., BMC, 2014 | Spain | 102 | II | 24.5 | 66.7 | 3.9 | 10 |
| Palacka et al., Klin Onkol, 2014 | Slovak Republic | 16 | II | 13.3 | – | 2.3 | 5.2 |
| Hegele et al., Urol Int, 2014 | Germany | 21 | II | 19.1 | 47.7 | 4.4 | 6.2 |
| Hussain et al., ASCO GU, 2015 | UK | 37 | II | 32 | 52.6 | – | 9.5 |
| Moriceau et al., Clin Genit, 2015 | France | 19 | II (47%) III or more (53%) | 32 | 53 | 2.9 | 5.6 |
| Retz et al., BMC, 2015 | Germany | 77 | II (66%) I (12%) III or more (22%) | 23.4 | 53.2 | – | 7.7 |
| Bellmunt et al., JCO, 2009 | Europe | 253 | II | 8.6 | 41 | 3 | 6.9 |
| Facchini et al. | Italy | 43 | II (81%) III or more (19%) | 12 | 29 | 2.2 | 6.9 |
REFERENCES

Albers, P., Siener, R., Hartlein, M., Fallahi, M., Haeutle, D., Perabo, F. G., et al. (2002). Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma – prognostic factors for response and improvement of quality of life. Onkologie 25, 47–52. doi: 10.1159/000055202

Aparicio, L. M., Pulido, E. G., and Gallego, G. A. (2012). Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 23, 1–11. doi: 10.1097/CAD.0b013e32834d237b

Bellmunt, J., Choueiri, T. K., Fougeray, R., Schutz, F. A., Salhi, Y., Winquist, E., et al. (2010). Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J. Clin. Oncol. 28, 1850–1855. doi: 10.1200/JCO.2009.25.4534

Bellmunt, J., Cos, J., Cleries, R., Pérez, M., Ribas, A., Eres, N., et al. (2002). Feasibility trial of methotrexate–paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 20, 673–685. doi: 10.1080/120003536

Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., et al. (2002). Vinflunine in the Treatment of Urothelial Cell Carcinoma. J. Clin. Oncol. 20, 158–165. doi: 10.1200/JCO.2002.10.2871

Bellmunt, J., Fougeray, R., Rosenberg, J. E., von der Maase, H., Schutz, F. A., Salhi, Y., et al. (2002). Vinflunine in the Treatment of Urothelial Cell Carcinoma. J. Clin. Oncol. 20, 158–165. doi: 10.1200/JCO.2002.10.2871

Facchini et al. Vinflunine in the Treatment of Urothelial Carcinoma

Galsky, M. D., Krege, S., Lin, C. C., Hahn, N. M., Ecke, T., Moshtier, E. L., et al. (2012). Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Abstract 4524 ASCO 2012. J. Clin. Oncol. 30(Suppl.) abstr 4524.

Hegele, A., de Geeter, P., Goebell, P., Matta, U., de Schultz, W., and Retz, M. (2013). Vinflunine in routine practice for the treatment of advanced or metastatic urothelial cell carcinoma in Germany. Eur. J. Cancer 49(Suppl. 2): S669.

Hussain, S. A., Ansari, J., Huddart, R. A., Wylie, J., Villarino-Varela, M., Faust, G., et al. (2015). VICTOR: Vinflunine (Vin) in advanced metastatic transitional cell carcinoma of the urothelium (TCCU)—A retrospective analysis of use of Vin in multicontext, real life setting as second-line chemotherapy (CHT) through free-of-charge-programme (FOCP) for patients (pts) in the UK. J. Clin. Oncol. 33(Suppl. 7):eabstr 552.

Iaffaioli, R. V., Facchini, G., Tortorillo, A., Crovella, F., Romano, G., Formato, R., et al. (2006). Stop Flow in abdominal and pelvic cancer relapses. Front. Biol. 11:1288. doi: 10.2741/1882

Iaffaioli, R. V., Massidda, B., Facchini, G., Tortorillo, A., Santangelo, M., Crovella, M., et al. (1997). Abdominal and pelvic stop-flow (hypoxic, chemotherapeutic loco-regional treatment): preliminary report of a phase I study. Eur. J. Cancer 33:5252. doi: 10.1016/S0959-8497(97)00532-2

Kruzeigenys, A., and Hill, B. L. (2001). Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit. Rev. Oncol. Hematol. 40, 159–173. doi: 10.1016/S1040-4821(00)00183-4

Leopardo, D., Cecere, S. C., Di Napoli, M., Cavaliere, C., Pisano, C., Striano, S., et al. (2013). Intravesical chemo-immunotherapy in non muscle invasive bladder cancer. Eur. Rev. Med. Pharmacol. Sci. 17, 2145–2158.

Lin, C. C., Hsu, C. H., Huang, C. Y., Keng, H. Y., Tsai, Y. C., Huang, K. H., et al. (2007). Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18, 487–491. doi: 10.1097/CAD.0b013e3280266063

Marra, L., Cantele, M., Scompropigno, G., Perdonà, M., La Mantia, E., Cerrone, M., et al. (2013). Deregulation of HOX B13 expression in urinary bladder cancer. Prog. Mol. Biol. Transl. Sci. 14:779.

Marra, M., Santini, D., Tonini, G., Meo, G., Zappavigna, S., Facchini, G., et al. (2008). Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. Eur. J. Cancer Suppl. 6, 79–85. doi: 10.1016/j.ejcsup.2008.06.023

Medioni, J., Guillot, A., Saeth, D., Di Palma, M., and Theoret, C. (2013). Historical data in real life from patients treated by vinflunine for an advanced or metastatic urothelial carcinoma: results of the CURVE study. Eur. J. Cancer Suppl. 2, S646–S647.

Moriceau, G., Vallard, A., Rivoirard, R., Méry, E., Espenel, S., Langrand-Escure, J., et al. (2015). Real-world vinflunine outcomes in bladder cancer in a single-institution study: moving beyond clinical trials. Clin. Genitourin. Cancer 13, 588–592. doi: 10.1016/j.clgc.2015.05.008

Palacka, P., Mego, M., Obertova, J., Chovanec, M., Sycova-Mila, Z., and Mardiak, J. (2014). The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas. Klin. Onkol. 27, 429–433. doi: 10.14735/amko2014429

Pisano, C., Marra, M., Palacka, P., Mego, M., Kobalz, L., and Albers, P. (2006). German Association Of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int. J. Clin. Pract. 60, 27–31.

Retz, M., de Geeter, P., Goebell, P. J., Matz, U., de Schultz, W., and Hegele, A. (2015). Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma – datafrom a prospective, multicenter experience. BMC Cancer. 15:455. doi: 10.1186/s12885-015-1434-3

Roberts, J. T., von der Maase, H., Sengelov, L., Conte, P. F., Fogliatti, L., Oliver, T., et al. (2006). Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 17, 118–122. doi: 10.1093/annonc/mdg965

Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics (2013) CA Cancer. J. Clin. 63, 11–30. doi: 10.3322/caac.21166

Sonpavde, G., Pond, G. R., Fougeray, R., Choueiri, T. K., Qu, A. Q., Vaughan, D. J., et al. (2013). Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur. Urol. 63, 717–723. doi: 10.1016/j.eururo.2012.11.042

Sternberg, C. N., Calabro, F., Pizzocaro, G., Marin, I., Schnetzer, S., and Sella, A. (2001). Chemotherapy with an every 2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received
Facchini et al. (2009). Vinflunine in platinum pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115, 4110–4117. doi: 10.1002/cncr.24460

Von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., et al. (2005). Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608. doi: 10.1200/JCO.2005.07.757

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Facchini, Della Pepa, Cavaliere, Cecere, Di Napoli, D’Aniello, Crispo, Iovane, Maiolino, Tramontano, Pisconti, Montella, Berretta, Sorrentino, Perdonà and Pignata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.